Skip to main content
OpenTrials

Clinical trial condition

Mucopolysaccharidosis I

Explore clinical trials studying Mucopolysaccharidosis I. Study availability and eligibility vary by location and protocol.

25 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Mucopolysaccharidosis I trial results

Completed

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

NCT02371226

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +9 more
Locations
  • Children's Hospital Oakland Oakland, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Emory Healthcare Decatur, Georgia, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
View Trial Details
Completed

Human Placental-Derived Stem Cell Transplantation

NCT01586455

Conditions
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Adrenal Gland Diseases, +84 more
Locations
  • Children's Hospital Colorado Denver, Colorado, United States
  • New York Medical College Valhalla, New York, United States
  • University of Utah Salt Lake City, Utah, United States
View Trial Details
Completed

Stem Cell Transplant w/Laronidase for Hurler

NCT00176891

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +10 more
Locations
  • Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
View Trial Details
Completed

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

NCT00852358

Conditions
Carbohydrate Metabolism, Inborn Errors, Cognition Disorders, Cognitive Decline, +17 more
Locations
  • Children's Hospital & Research Center Oakland Oakland, California, United States
  • Los Angeles Biomedical Institute at Harbor-UCLA Torrance, California, United States
  • University of Minnesota Minneapolis, Minnesota, United States
View Trial Details
Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

NCT00144781

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • Hospital Infantil Joana de Gusmao Florianópolis, Santa Catarina, Brazil
  • Universidade Federal de Minas Gerais Belo Horizonte, Brazil
  • Hospital de Clinical de Porto Alegre Porto Alegre, Brazil
  • Universidade Federal de Sao Paulo São Paulo, Brazil
View Trial Details
Completed

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

NCT00146757

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • Hôpital E. Herriot Lyon, France
  • Johannes Gutenberg Universität Kinderklinik, Mainz, Germany
  • Sophia Children's Hospital Rotterdam, Netherlands
  • Willink Biochemical Genetics Unit Royal Hospital for Children Manchester, United Kingdom
View Trial Details
Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

NCT00146770

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
  • University of Rochester Rochester, New York, United States
  • University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
View all 25 locations
View Trial Details

Related conditions